It’s a David-and-Goliath fight between two unprofitable startups.
Moderna Therapeutics is valued by its private investors at $5 billion, as it promises to create a new kind of medicine that will turn the body’s own cells into factories for vaccines and treatments. Arbutus Biopharma, a publicly traded firm, has a market capitalization of just $187 million.
